Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection

Journal of Immunology

Volumn 166, Issue 11, 2001, Pages 6555-6563

  Soares, M Melina ^a   Mehta, Vinay ^b   Finn, Olivera J ^a,c  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b WASHINGTON AND JEFFERSON COLLEGE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; GAMMA INTERFERON; GLYCOPROTEIN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN M; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MUCIN; T LYMPHOCYTE ANTIBODY; T LYMPHOCYTE ANTIGEN; TUMOR ANTIGEN; TUMOR VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CANCER PATIENT; CELLULAR IMMUNITY; CONTROLLED STUDY; DENDRITIC CELL; DRUG SAFETY; ENDOCYTOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SUPPRESSOR CELL; TANDEM REPEAT; TH1 CELL; TRANSGENIC MOUSE; TUMOR GROWTH; TUMOR REJECTION;

EID: 0035339389     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.166.11.6555     Document Type: Article

References (75)

1. Gendler, S. J., and A. P. Spicer. 1995. Epithelial mucin genes. Annu. Rev. Physiol. 57:607.
2. Soares, M. M., and O. J. Finn. MUC1 mucin as a target for immunotherapy of cancer. In Cancer Immunology, Immunology in Medicine Series. R. Rees and A. Robbins, eds. Kluver Academic Publishers. In press.
3. Hanisch, F. G., T. R. Stadie, F. Deutzmann, and J. Peter-Katalinic. 1996. MUC1 glycoforms in breast cancer cell line T47D as a model for carcinoma-associated alteralions of O-glycosylation. Eur. J. Biochem. 236:318.
4. Lancaster, C. A., N. Peat, T. Duhig, D. Wilson, J. Taylor-Papadimitriou, and S. J. Gendler. 1990. Structure and expression of the human polymorphic epithelial mucin gene: an expressed VNTR unit. Biochem. Biophys. Res. Commun. 173:1019.
5. Muller, S., S. Goletz, N. Packer, A. Gooley, A. M. Lawson, and F. G. Hanisch. 1997. Localization of O-glycosylation sites on glycopeptide fragments from lactation-associated MUC1: all putative sites within the tandem repeat are glycosylation targets in vivo. J. Biol. Chem. 272:24780.
6. Brockhausen, I., J. M. Yang, J. Burchell, C. Whitehouse, and J. Taylor-Papadimitriou. 1995. Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cells. Eur. J. Biochem. 233:607.
7. Nishimori, I., F. Perini, K. P. Mountjoy, S. D. Sanderson, N. Johnson, R. L. Cerny, M. L. Gross, J. D. Fontenot, and M. A. Hollingsworth. 1994. N-acetylgalactosamine glycosylation of MUC1 tandem repeat peptides by pancreatic tumor cell extracts. Cancer Res. 54:3738.
8. Seregni, E., C. Botti, S. Massaron, C. Lombardo, A. Capobianco, A. Bogni, and E. Bombardieri. 1997. Structure, function and gene expression of epithelial mucins. Tumor 83:625.
9. Stadie, T. R., W. Chai, A. M. Lawson, P. G. Byfield, and F. G. Hanisch. 1995. Studies on the order and site specificity of GalNAc transfer to MUC1 tandem repeats by UDP-GalNAc: polypeptide N-acetylgalactosaminyltransferase from milk or mammary carcinoma cells. Eur. J. Biochem. 229:140.
10. Kotera, Y., J. D. Fontenot, G. Pecher, R. S. Metzgar, and O. J. Finn. 1994. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res. 54:2856.
11. Petrarca, C., B. Casalino, S. von Mensdorff-Pouilly, A. Rughetti, H. Rahimi, G. Scambia, J. Hilgers, L. Frati, and M. Nuti. 1999. Isolation of MUC1-primed B lymphocytes from tumour-draining lymph nodes by immunomagnetic beads. Cancer Immunol. Immunother. 47:272.
12. Richards, E. R., P. L. Devine, R. J. Quin., J. D. Fontenot., B. G. Ward, and M. A. McGuckin. 1998. Antibodies reactive with the protein core of MUC1 mucin are present in ovarian cancer patients and healthy women. Cancer Immunol. Immunother. 46:245.
13. Rughetti, A., V. Turchi, C. A. Ghetti, G. Scambia, P. B. Panici, G. Roncucci, S. Mancuso, L. Frati, and M. Nuti. 1993. Human B-cell immune response to the polymorphic epithelial mucin. Cancer Res. 53:2457.
14. von Mensdorff-Pouilly, S., M. M. Gourevitch, P. Kenemans, A. A. Verstraeten, S. V. Litvinov, G. J. van Kamp, S. Meijer, J. Vermorken, and J. Hilgers. 1996. Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumour. Eur. J. Cancer. 32A:1325.
15. von Mensdorff-Pouilly, S., C. Vennegoor, and J. Hilgers. 2000. Detection of humoral immune responses to mucins. Methods Mol. Bio. 125:495.
16. Brossart, P., K. S. Heinrich, G. Stuhler, L. Behnke, V. L. Reichardt, S. Stevanovic, A. Muhm, H. G. Rammensee, L. Kanz, and W. Brugger. 1999. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 93:4309.
17. Domenech, N., R. A. Henderson, and O. J. Finn. 1995. Identification of an HLA-A11-restricted epitope from the tandem repeat domain of the epithelial tumor antigen mucin. J. Immunol. 155:4766.
18. Jerome, K. R., D. L. Barnd, K. M. Bendt, C. M. Boye, J. Taylor-Papadimitriou, I. F. McKenzie, R. C. Bast Jr., and O. J. Finn. 1991. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 51:2908.
19. Jerome, K. R., N. Domenech, and O. J. Finn. 1993. Tumor-specific cytotoxic T cell clones from patients with breast and pancreatic adenocarcinoma recognize EBV-immortalized B cells transfected with polymorphic epithelial mucin complementary DNA. J. Immunol. 151:1654.
20. McKolanis, J. R., and O. J. Finn. 2000. Analysis of the frequency of MHC-unrestricted MUC1-specitic cytotoxic T-cells in peripheral blood by limiting dilution assay. Methods Mol. Bio. 125:463.
21. Hiltbold, E. M., M. D. Alter, P. Ciborowski, and O. J. Finn. 1999. Presentation of MUC1 tumor antigen by class I MHC and CTL function correlate with the glycosylation state of the protein taken up by dendritic cells. Cell. Immunol. 194:143.
22. Hiltbold, E. M., A. M. Vlad, P. Ciborowski, S. C. Watkins, and O. J. Finn. 2000. The mechanism of unresponsiveness to circulating tumor antigen MUC1 is a block in intracellular sorting and processing by dendritic cells. J. Immunol. 165: 3730.
23. + T cells. Cancer Res. 58:5066.
24. Goydos, J. S., E. Elder, T. L. Whiteside, O. J. Finn, and M. T. Lotze. 1996. A phase I trial of a synthetic mucin peptide vaccine: induction of specific immune reactivity in patients with adenocarcinoma. J. Surgical Res. 63:298.
25. Longenecker, B. M., M. Reddish, R. Koganty, and G. D. MacLean. 1993. Immune responses of mice and human breast cancer patients following immunization with synthetic sialyl-Tn conjugated to KLH plus detox adjuvant. Ann. NY Acad. Sci. 690:276.
26. Scholl, S., B. Acres, C. Schatz, M. P. Kieny, J. M. Balloul, A. Vincent-Salomon, L. Deneux, E. Tartour, H. Fridman, and P. Pouillart. 1997. The polymorphic epithelial mucin (MUC1): a phase I clinical trial testing the tolerance and immunogenecity of a vaccinia virus-MUC1-IL-2 construct in breast cancer. Breast Cancer Res. Treat. 46:67.
27. Karanikas, V., L. A. Hwang, J. Pearson, C. S. Ong, V. Apostolopoulos, H. Vaughan, P. X. Xing, G. Jamieson, G. Pietersz, B. Tait, R. et al. 1997. Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. J. Clin. Investigation. 100:2783.
28. Acres, R. B., M. Hareuveni, J. M. Balloul, and M. P. Kieny. 1993. Vaccinia virus MUC1 immunization of mice: immune response and protection against the growth of murine tumors bearing the MUC1 antigen. J. Immunother. 14:136.
29. Akagi, J., J. W. Hodge, J. P. McLaughlin, L. Gritz, G. Mazzara, D. Kufe, J. Schlom, and J. A. Kantor. 1997. Therapeutic antitumor response after immunization with an admixture of recombinant vaccinia viruses expressing a modified MUC1 gene and the murine T-cell costimulatory molecule B7. J. Immunother. 20:38.
30. Apostolopoulos, V., G. A. Pietersz, B. E. Loveland, M. S. Sandrin, and I. F. McKenzie. 1995. Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. Proc. Natl. Acad. Sci. USA 92:10128.
31. Apostolopoulos, V., G. A. Pietersz, P. X. Xing, C. J. Lees, M. Michael, J. Bishop, and I. F. McKenzie. 1995. The immunogenicity of MUC1 peptides and fusion protein. Cancer Lett. 90:21.
32. Apostolopoulos, V., G. A. Pietersz, and I. F. McKenzie. 1996. Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. Vaccine 14:930.
33. Apostolopoulos, V., V. Popovski, and I. F. McKenzie. 1998. Cyclophosphamide enhances the CTL precursor frequency in mice immunized with MUC1-mannan fusion protein (M-FP). J. Immunother. 21:109.
34. Ding, L., E. N. Lalani, M. Reddish, R. Koganty, T. Wong, J. Samuel, M. B. Yacyshyn, A. Meikle, P. Y. Fung, J. Taylor-Papadimitriou, and B. Longenecker. 1993. Immunogenicity of synthetic peptides related to the core peptide sequence encoded by the human MUC1 mucin gene: effect of immunization on the growth of murine mammary adenocarcinoma cells transfected with the human MUC1 gene. Cancer Immunol. Immunother. 36:9.
35. Gong, J., D. Chen, M. Kashiwabam, and D. Kufe. 1997. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nature Med. 3:558.
36. Graham, R. A., J. M. Burchell, P. Beverley, and J. Taylor-Papadimitriou. 1996. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Intl. J. Cancer. 65:664.
37. Henningsson, C. M., S. Selvaraj, G. D. MacLean, M. R. Suresh, A. A. Noujaim, and B. M. Longenecker. 1987. T cell recognition of a tumor-associated glycoprotein and its synthetic carbohydrate epitopes: stimulation of anticancer T cell immunity in vivo. Cancer Immunol. Immunother. 25:231.
38. Kieber-Emmons, T., P. Luo, J. Qiu, T. Y. Chang, M. Blaszczyk-Thurin, and Z. Steplewski. 1999. Vaccination with carbohydrate peptide mimotopes promotes anti-tumor responses. Nat. Biotech. 17:660.
39. Newman, K. D., D. L. Sosnowski, G. S. Kwon, and J. Samuel. 1998. Delivery of MUC1 mucin peptide by poly(D,L-lactic-co-glycolic acid) microspheres induces type 1 T helper immune responses. J. Pharm. Sci. 87:1421.
40. Samuel, J., W. A. Budzynski, M. A. Reddish, L. Ding., G. L. Zimmermann, M. J. Krantz, R. R. Koganty, and B. M. Longenecker. 1998. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine. Intl. J. Cancer. 75:295.
41. Barratt-Boyes, S. M., H. Kao, and O. J. Finn. 1998. Chimpanzee dendritic cells derived in vitro from blood monocytes and pulsed with antigen elicit specific immune responses in vivo. J. Immunother. 21:142.
42. Barratt-Boyes, S. M., A. Vlad, and O. J. Finn. 1999. Immunization of chimpanzees with tumor antigen MUC1 mucin tandem repeat peptide elicits both helper and cytotoxic T-cell responses. Clin. Cancer Res. 5:1918.
43. Pecher, G., and O. J. Finn. 1996. Induction of cellular immunity in chimpanzees to human tumor-associated antigen mucin by vaccination with MUC-1 cDNA-transfected Epstein-Barr virus-immortalized autologous B cells. Proc. Natl. Acad. Sci. USA 93:1699.
44. Clarke, P., J. Mann, J. F. Simpson, K. Rickard-Dickson and F. J. Primus. 1998. Mice transgenic for human carcinoembryonic antigen as a model for immunotherapy. Cancer Res. 58:1469.
45. Kass, E., J. Schlom, J. Thompson, F. Guadagni, P. Graziano, and J. W. Greiner. 1999. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus. Cancer Res. 59:676.
46. Mizobata, S., K. Tompkins, J. F. Simpson, Y. Shyr, and F. J. Primus. 2000. Induction of cytotoxic T cells and their antitumor activity in mice transgenic for carcinoembryonic antigen. Cancer Immunol. Immunother. 49:285.
47. Xu, X., P. Clarke, G. Szalai, J. E. Shively, L. E. Williams, Y. Shyr, E. Shi, and F. J. Primus. 2000. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein. Cancer Res. 60:4475.
48. Boggio, K., G. Nicoletti, E. Di Carlo, F. Cavallo, L. Landuzzi, C. Melani, M. Giovarelli, I. Rossi, P. Nanni, C. De Giovanni, et al. 1998. Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. J. Exp. Med. 188:589.
49. Esserman, L. J., T. Lopez, R. Montes, L. N. Bald, B. M. Fendly, and M. J. Campbell. 1999. Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice. Cancer Immunol. Immunother. 47:337.
50. Reilly, R. T., M. B. Gottlieb, A. M. Ercolini, J. P. Machiels, C. E. Kane, F. I. Okoye, W. J. Muller, K. H. Dixon, and E. M. Jaffee. 2000. HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice. Cancer Res. 60: 3569.
51. Carr-Brendel, V., D. Markovic, K. Ferrer, M. Smith, J. Taylor-Papadimitriou, J., and E. P. Cohen. 2000. Immunity to murine breast cancer cells modified to express MUC-1, a human breast cancer antigen, in transgenic mice tolerant to human MUC-1. Cancer Res. 60:2435.
52. Gong, J., D. Chen, L. Kashiwaba, Y. Li, L. Chen, H. Takeuchi, H. Qu, G. J. Rowse, S. J. Gendler, and D. Kufe. 1998. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl. Acad. Sci. USA 95:6279.
53. Rowse, G. J., R. M. Tempero, M. L. VanLith, M. A. Hollingsworth, and S. J. Gendler. 1998. Tolerance and immunity to MUC1 in a human MUC1 transgenic murine model. Cancer Res. 58:315.
54. Smith, M., J. M. Burchell, R. Graham, E. P. Cohen, and J. Taylor-Papadimitriou. 1999. Expression of B7.1 in a MUC1-expressing mouse mammary epithelial tumour cell line inhibits tumorigenicity but does not induce autoimmunity in MUC1 transgenic mice. Immunol. 97:648.
55. + lymphocytes provide MUC1-specific tumor immunity in vivo that is undetectable in vitro and is absent in MUC1 transgenic mice. J. Immunol. 161:5500.
56. Ling, I. T., S. A. Ogun, P. Momin, R. L. Richards, N. Garcon, J. Cohen, W. R. Ballou, and A. A. Holder. 1997. Immunization against the murine malaria parasite Plasmodium yoelii using a recombinant protein with adjuvants developed for clinical use. Vaccine 15:1562.
57. Stoute, J. A., M. Slaoui, D. G. Heppner, P. Momin, K. E. Kester, P. Desmons, B. T. Wellde, N. Garcon, U. Krzych, and M. Marchand. 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria: RTS, S malaria vaccine evaluation. New Eng. J. Med. 336:86.
58. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1:1297.
59. Prussin, C., and D. D. Metcalfe. 1995. Detection of intracytoplasmic cytokine using flow cytometry and directly conjugated anti-cytokine antibodies. J. Immunol. Methods 188:117.
60. Isakson, P. C., E. Pure, E. S. Vitetta, and P. H. Krammer. 1982. T cell-derived B cell differentiation factor(s): effect on the isotype switch of murine B cells. J. Exp. Med. 155:734.
61. McIntyre, T. M., D. R. Klinman, P. Rothman, M. Lugo, J. R. Dasch, J. J. Mond, and C. M. Snapper. 1993. Transforming growth factor β 1 selectivity stimulates immunoglobulin G2b secretion by lipopolysaccharide-activated murine B cells. J. Exp. Med. 177:1031.
62. Snapper, C. M., T. M. McIntyre, R. Mandler, L. M. Pecanha, F. D. Finkelman, A. Lees, and J. J. Mond. 1992. Induction of IgG3 secretion by interferon γ: a model for T cell-independent class switching in response to T cell-independent type 2 antigens. J. Exp. Med. 175:1367.
63. Martin, R. M., and A. M. Lew. 1998. Is IgG2a a good Th1 marker in mice? Immunol. Today 19:49.
64. Acres, B., V. Apostolopoulos, J. M. Balloul, D. Wreschner, P. X. Xing, D. Ali-Hadji, N. Bizouarne, M. P. Kieny, and I. F. McKenzie. 2000. MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines. Cancer Immunol. Immunother. 48:588.
65. Tempero, R. M., G. J. Rowse, S. J. Gendler, and M. A. Hollingsworth. 1999. Passively transferred anti-MUC1 antibodies cause neither autoimmune disorders nor immunity against transplanted tumors in MUC1 transgenic mice. Intl. J. Cancer. 80:595.
66. Wilder, J. A., C. Y. Koh, and D. Yuan. 1996. The role of NK cells during in vivo antigen-specific antibody responses. J. Immunol. 156:146.
67. Koh, C. Y., and D. Yuan. 1997. The effect of NK cell activation by tumor cells on antigen-specific antibody responses. J. Immunol. 159:4745.
68. Orange, J. S., and C. A. Biron. 1996. Characterization of early IL-12, IFN-αβ, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection. J. Immunol. 156:4746.
69. Gerard, C. M., N. Baudson, K. Kraemer, C. Ledent, Y. Paterson, Z. K. Pan, D. Pardoll, and C. Bruck. 2000. Recombinant HPV16 E7 protein as a model antigen to study the vaccine potential in control and E7 transgenic mice. Clin. Cancer Res. 7:838s.
70. Bright, R. K., M. H. Shearer, and R. C. Kennedy. 1994. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells: an antibody-based mechanism for tumor immunity. J. Immunol. 153:2064.
71. Guidotti, L. G., P. Borrow, A. Brown, H. McClary, R. Koch, and F. V. Chisari. 1999. Noncytopathic clearance of lymphocytic choriomeningitis virus from the hepatocyte. J. Exp. Med. 189:1555.
72. Guidotti, L. G., R. Rochford, J. Chung, M. Shapiro, R. Purcell, and F. V. Chisari. 1999. Viral clearance without destruction of infected cells during acute HBV infection. Science 284:825.
73. - T cells can block herpes simplex virus type 1 (HSV-1) reactivation from latency in sensory neurons. J. Exp. Med. 191:1459.
74. Peng, L., J. C. Krauss, G. E. Plautz, S. Mukai, S. Shu, and P. A. Cohen. 2000. T cell-mediated tumor rejection displays diverse dependence upon perforin and IFN-γ mechanisms that cannot be predicted from in vitro T cell characteristics. J. Immunol. 165:7116.
75. Sparwasser, T., R. M. Vabulas, B. Villmow, G. B. Lipford, and H. Wagner. 2000. Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins. Eur. J. Immunol. 30:3591.